

Elizabeth H.S. Wyatt  
Vice President  
Corporate Licensing

Merck & Co., Inc.  
One Merck Drive  
P.O. Box 100, WS2A-30  
Whitehouse Station NJ 08889-0100

**CONFIRMATION**

*cc'd to Dennis & Craig*

Fax 908 735 1202  
Tel 908 423 4350

March 9, 1999



Dr. Robert H. Harris  
President  
Federal Research Consultants  
2139 Route 35  
Holmdel, NJ 07733

Dear Dr. Harris:

Thank you for your letter of January 12, 1999.

The additional information provided on Harkoseride (ADD 234037), a novel antiepileptic with neuroprotective properties, has been recently reviewed by the Neuroscience Review and Licensing Committee, part of the Merck Research Laboratories (MRL). We regret that there is no current interest in pursuing further evaluation of the opportunity on the basis of unclear mechanism of action and AEs.

We do, however, thank you for thinking of Merck.

Sincerely,

A handwritten signature in black ink, appearing to read "Elizabeth H.S. Wyatt", written in a cursive style.

Elizabeth H.S. Wyatt

cc: Mr. Dennis Miller

/ie  
[151074.doc]  
etts1214

*[Faint, illegible text, likely bleed-through from the reverse side of the page]*